MA36970A1 - Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels - Google Patents

Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels

Info

Publication number
MA36970A1
MA36970A1 MA36970A MA36970A MA36970A1 MA 36970 A1 MA36970 A1 MA 36970A1 MA 36970 A MA36970 A MA 36970A MA 36970 A MA36970 A MA 36970A MA 36970 A1 MA36970 A1 MA 36970A1
Authority
MA
Morocco
Prior art keywords
receptor
endothelin
artificial transcription
transcription factors
expression
Prior art date
Application number
MA36970A
Other languages
English (en)
French (fr)
Inventor
Josef Flammer
Albert Neutzner
Alice Huxley
Original Assignee
Aliophtha Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aliophtha Ag filed Critical Aliophtha Ag
Publication of MA36970A1 publication Critical patent/MA36970A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA36970A 2011-10-11 2012-10-10 Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels MA36970A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11184706 2011-10-11
PCT/EP2012/069981 WO2013053719A2 (en) 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors

Publications (1)

Publication Number Publication Date
MA36970A1 true MA36970A1 (fr) 2016-03-31

Family

ID=47045011

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36970A MA36970A1 (fr) 2011-10-11 2012-10-10 Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels

Country Status (21)

Country Link
US (1) US20140296129A1 (https=)
EP (1) EP2766484A2 (https=)
JP (1) JP2014530607A (https=)
KR (1) KR20140079780A (https=)
CN (1) CN103998609A (https=)
AU (1) AU2012323032A1 (https=)
BR (1) BR112014008456A2 (https=)
CA (1) CA2851560A1 (https=)
CL (1) CL2014000897A1 (https=)
CO (1) CO6930308A2 (https=)
EA (1) EA201490531A1 (https=)
HK (1) HK1197083A1 (https=)
IL (1) IL231865A0 (https=)
IN (1) IN2014CN02586A (https=)
MA (1) MA36970A1 (https=)
MX (1) MX2014004331A (https=)
PH (1) PH12014500786A1 (https=)
SG (1) SG11201400701WA (https=)
TN (1) TN2014000117A1 (https=)
WO (1) WO2013053719A2 (https=)
ZA (1) ZA201401960B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
WO2019195285A1 (en) * 2018-04-02 2019-10-10 University Of Miami Ifn-beta reporter system for immortalized primary cells
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
AU2020405068A1 (en) 2019-12-18 2022-07-07 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
CN111304314B (zh) * 2020-02-25 2020-11-20 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用
US20220049310A1 (en) * 2020-02-25 2022-02-17 Sichuan Provincial People's Hospital Use of ZNF124 Gene in Early Screening or Auxiliary Diagnosis of Retinitis Pigmentosa Disease
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE524545T1 (de) * 1994-08-20 2011-09-15 Gendaq Ltd Verbesserungen bei oder im zusammenhang mit bindeproteinen zur erkennung von dna
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
AU2964101A (en) * 2000-01-21 2001-07-31 Scripps Research Institute, The Methods and compositions to modulate expression in plants
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
NZ527476A (en) * 2001-02-21 2006-06-30 Novartis Ag Zinc finger binding domains for nucleotide sequence ANN
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
EP1929032A4 (en) * 2005-09-30 2009-11-04 Oklahoma Med Res Found REGULATION OF GOOD LIKE RECEPTORS ON STEM CELLS
WO2008140538A1 (en) * 2006-10-04 2008-11-20 Verenium Corporation Dna display screen for expression product with desired binding properties
GB0620705D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
CN101333251A (zh) * 2008-01-30 2008-12-31 中国人民解放军第三军医大学 能启动a20基因表达的人工锌指蛋白转录因子及用途
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
EP2411518A2 (en) * 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna interference mediated inhibition of the high affinity ige receptor alpha chain (fcerla) gene expression using short interfering nucleic acid (sina)
EP2509594A1 (en) * 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis

Also Published As

Publication number Publication date
BR112014008456A2 (pt) 2017-04-11
ZA201401960B (en) 2015-06-24
MX2014004331A (es) 2014-11-26
EA201490531A1 (ru) 2014-08-29
IL231865A0 (en) 2014-05-28
EP2766484A2 (en) 2014-08-20
CL2014000897A1 (es) 2014-11-21
SG11201400701WA (en) 2014-08-28
AU2012323032A1 (en) 2014-04-03
JP2014530607A (ja) 2014-11-20
KR20140079780A (ko) 2014-06-27
PH12014500786A1 (en) 2021-08-09
HK1197083A1 (en) 2015-01-02
IN2014CN02586A (https=) 2015-08-07
CA2851560A1 (en) 2013-04-18
WO2013053719A3 (en) 2013-06-27
CO6930308A2 (es) 2014-04-28
CN103998609A (zh) 2014-08-20
US20140296129A1 (en) 2014-10-02
TN2014000117A1 (en) 2015-07-01
WO2013053719A2 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
MA36970A1 (fr) Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels
EP4248971A3 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
EP4477233A3 (en) A stable liquid formulation of fusion protein with igg fc domain
MY188987A (en) Aav vectors for retinal and cns gene therapy
FR2989179B3 (fr) Lentilles,des dispositifs, proceces et systemes destines a l'erreur de refraction
SG11201806502UA (en) Conjugate of therapeutic enzymes
MX2021012989A (es) Metodos y composiciones para modular el empalme y la traduccion.
WO2021097223A3 (en) Biparatopic cd73 antibodies
EP2657912A3 (en) Method of simulating lens using augmented reality
WO2007089375A3 (en) Compositions and methods for regulating complement system
MY207914A (en) Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
MA50280A (fr) Procédés et compositions pour améliorer l'immunogénicité de tumeurs [
WO2017106899A3 (en) Therapeutic methods using erythrocytes
WO2020264438A3 (en) Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
WO2020172482A3 (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
WO2023178280A3 (en) Compositions and methods for modulating alpha-synuclein expression
EP4389894A3 (en) Riboswitch modulated gene therapy for retinal diseases
MX391658B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
ZA202206245B (en) On-bipolar cell-specific promoters for ocular gene delivery
WO2022235551A3 (en) Fc-fusion protein therapeutic for the treatment of pancreatitis
WO2022198138A8 (en) Ocular delivery of therapeutic agents
EP4559529A3 (en) Isocyclosporin a for topical treatment of ocular diseases
JOP20220074A1 (ar) أجسام مضادة لـ nrp1a واستخداماتها لعلاج العين أو أمراض العين
MY178716A (en) Composition for treatment of ocular diseases and preparation thereof
HK40067296A (en) Pharmaceutical compositions for treating ocular diseases or disorders